Law360, New York (May 07, 2009, 12:00 AM ET) -- A group of state lawmakers has asked the Federal Trade Commission to investigate whether the 2007 merger that created CVS Caremark Corp. has led to fraudulent and anti-competitive conduct, hurting prescription drug consumers.
Sharon Anglin Treat, executive director of the National Legislative Association on Prescription Drug Prices, said in a letter to FTC Chairman Jon Leibowitz on Thursday that the combination of CVS, a pharmacy operator, and Caremark, a pharmacy benefit manager, created opportunities for the company to enrich itself at the expense of competition and...
State Lawmakers Call For FTC To Probe CVS Caremark
To view the full article, take a free trial now.
